/Investor DB

BGV — 2022 Investments

3 investments dated 2022 · listed companies and verified rows first · show all

Complement Therapeuticscomplementtx.comFeb 2022

Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration.

BiotechDigital HealthHealthtechMedical DevicesMunich, DE

Rafiq Hasan(CEO and Managing Director)inMuhammad Ali Memon(Chief Medical Officer)in

Co-investorsBioGeneration VenturesCambridge Innovation CapitalGimvHadean VenturesSeroba Life SciencesForbion+2 more

Everest Labseverestlabs.aiin𝕏Sep 2022 · $16.1M

EverestLabs builds RecycleOS, an AI-powered operating system for recycling plants that uses computer vision, AI, and robotics to identify and sort recyclable materials in Material Recovery Facilities (MRFs).

AI & Machine LearningCircular EconomyClimate TechImpact & Social GoodRoboticsFremont, US

JD Ambati(Founder/Chief Strategy Officer)inR Paul Singh(CEO)in

Co-investorsBenhamou Global VenturesHike VenturesSierra VenturesTransLink CapitalUnanimous CapitalXplorer Capital+1 more

Phlox Therapeuticsphloxtherapeutics.cominMay 2022

Phlox Therapeutics develops RNA-based precision genetic medicines and gene therapies to treat and potentially cure rare genetic heart diseases such as cardiomyopathies and laminopathies.

BiotechHealthtechNaarden, NL

Co-investorsROM Utrecht RegionUvA Ventures Holding

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.